tirzepatide causing pancreatitis Small risk of severe acute with weight-loss jabs, UK regulator warns | Weight-loss drugs Tirzepatide and Pancreatitis Risk: Safe

Administering the injection on the same day each week ensures stable plasma concentrations and optimal efficacy

Baechler BL, Bloemberg D, Quadrilatero J

Phase 2 data published in the NEJM (2023) demonstrated up to 24.2% body weight reduction at 48 weeks among the highest observed for any pharmacological agent in obesity trials

However, treatment of MCF-7 and T47D cells with the DHODH activator DHO did not rescue palbociclib, RSL3, or combination-induced cell death

However, with only four cases and single-center data, this limits the generalizability of our findings and precludes any definitive conclusions regarding causality